In the phase III KAITLIN study (NCT01966471), T‐DM1 plus pertuzumab (AC‐KP) with taxane plus trastuzumab plus pertuzumab (AC‐THP) was administered after anthracycline‐based therapy in high‐risk HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.